Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Investor Presentation
Q3 FY25
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Ipca Laboratories Ltd (IPCALAB) is currently trading at 1,498.75 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Ipca Laboratories Limited is a fully integrated pharmaceutical company manufacturing and selling over 350 formulations and 80 APIs globally, operating in over 100 countries. Recently, Ipca has acquired a significant stake in Unichem Laboratories, which is expected to bring strategic synergies and expand its international market presence. Despite challenges like GST rate rationalizations, Ipca's domestic formulations business grew by 11.6% in Q2 FY26, outpacing the industry growth of 7.8%. Ipca's API business reports robust growth, with the Q2 FY26 showing a 28% increase driven by strong performance in Europe and Latin America. Increased R&D expenditure, now at 3.91% of turnover, signals Ipca’s commitment to innovation and future preparedness, especially in biosimilars and new market filings.
Over the past 52 weeks, Ipca Laboratories Ltd has traded between a low of ₹1,200.00 and a high of ₹1,594.55. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Ipca Laboratories Ltd has a market capitalization of approximately 38,055.63. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Ipca Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 36.26 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 38,055.63 Cr, Ipca Laboratories Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Ipca Laboratories Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Ipca Laboratories Ltd is 36.26. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
It is a ₹10,000 crore, five-year initiative aimed at making India a global biopharma manufacturing hub by supporting domestic production of biologics, biosimilars, and strengthening the R&D ecosystem.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1184.00 | 68,819 Cr | 19.47 | 1.96 | 0.00 | 9.77 | 12.69 | 6.63 | |
5475.55 | 65,525 Cr | 27.26 | 4.91 | 0.82 | 17.69 | 18.13 | 11.95 | |
2028.90 | 57,325 Cr | 21.15 | 5.98 | 0.12 | 26.24 | 30.84 | 5.60 | |
1011.10 | 54,677 Cr | 64.73 | 11.38 | 0.12 | 14.23 | 15.05 | 8.94 | |
1507.30 | 38,056 Cr | 36.26 | 5.12 | 0.27 | 13.33 | 17.89 | 7.73 | |
164.30 | 21,840 Cr | — | 2.70 | 0.08 | -0.29 | 4.50 | -1.01 | |
770.00 | 15,153 Cr | 22.81 | 2.85 | 1.43 | 11.93 | 12.59 | 7.45 |
Financial Results
Ipca Laboratories published extract of unaudited consolidated and standalone results for quarter and nine months ended Dec 31, 2025: consolidated revenue ₹2,392.50cr (Q3), consolidated PAT ₹326.27cr (Q3) and 9M PAT ₹842.05cr; Board approved Feb 13, 2026; limited review unmodified.
Financial Results
Ipca Laboratories published an extract of unaudited consolidated and standalone Q3 (Dec 31, 2025) and 9M results in newspapers; consolidated revenue Rs2,392.50cr and PAT after tax Rs326.27cr for the quarter; Board approved Feb 13, 2026; limited review unmodified.
Financial Results
Ipca Laboratories announced unaudited standalone and consolidated Q3 FY26 results (quarter ended Dec 31, 2025): Q3 revenue Rs1,845.18cr, PBT Rs417.22cr, PAT Rs303.45cr; 9M revenue Rs5,522.40cr, 9M PAT Rs870.23cr; limited review unmodified.
Financial Results
Ipca Laboratories reported standalone and consolidated unaudited Q3FY26 and 9M FY26 results: Q3 revenue Rs 1,845.18 Cr, PBT Rs 417.22 Cr, PAT Rs 303.45 Cr; 9M revenue Rs 5,522.40 Cr, PAT Rs 870.23 Cr; board approved, limited review unmodified.
Board Meeting Outcome
Board approved unaudited standalone and consolidated Q3 and nine‑month FY26 results for period ended Dec 31, 2025: Q3 revenue ₹1,845.18 Cr, PBT ₹417.22 Cr, PAT ₹303.45 Cr; 9M revenue ₹5,522.40 Cr, PAT ₹870.23 Cr; limited review unmodified.
Financial Results
Board approved unaudited standalone and consolidated Q3 and nine‑months FY26 results: Q3 revenue ₹1,845.18 Cr, Q3 PBT ₹417.22 Cr, Q3 PAT ₹303.45 Cr; 9M total income ₹5,587.16 Cr, limited review unmodified.
Bearish
4
Neutral
5
Bullish
5
Bearish
5
Neutral
5
Bullish
36
Bearish
1
Neutral
0
Bullish
31
Ipca Laboratories Limited is a fully integrated pharmaceutical company manufacturing and selling over 350 formulations and 80 APIs globally, operating in over 100 countries.
Recently, Ipca has acquired a significant stake in Unichem Laboratories, which is expected to bring strategic synergies and expand its international market presence.
Despite challenges like GST rate rationalizations, Ipca's domestic formulations business grew by 11.6% in Q2 FY26, outpacing the industry growth of 7.8%.
Ipca's API business reports robust growth, with the Q2 FY26 showing a 28% increase driven by strong performance in Europe and Latin America.
Increased R&D expenditure, now at 3.91% of turnover, signals Ipca’s commitment to innovation and future preparedness, especially in biosimilars and new market filings.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg
38,056 Cr
Low Risk
36.3
26.3
1.7
5.1
1,594.55
1,200.00
Sales CAGR
Profit CAGR
ROE
ROCE
